CC BY-NC-ND 4.0 · World J Nucl Med 2014; 13(03): 178-183
DOI: 10.4103/1450-1147.144818
Original article

Correlative 99m Tc-labeled tropane derivative single photon emission computer tomography and clinical assessment in the staging of parkinson disease

Ajit Shinto
Department of Nuclear Medicine, KMCH, Coimbatore, Tamil Nadu, India
,
Joppy Antony
Department of Nuclear Medicine, KMCH, Coimbatore, Tamil Nadu, India
,
Koramadai Kamaleshwaran
Department of Nuclear Medicine, KMCH, Coimbatore, Tamil Nadu, India
,
Krishnan Vijayan
1   Department of Neurology, KMCH, Coimbatore, Tamil Nadu, India
,
Arul Selvan
1   Department of Neurology, KMCH, Coimbatore, Tamil Nadu, India
,
Aruna Korde
2   Isotope Application and Radiopharmaceuticals Division, BARC, Mumbai, Maharashtra, India
,
Mythili Kameshwaran
2   Isotope Application and Radiopharmaceuticals Division, BARC, Mumbai, Maharashtra, India
,
Grace Samuel
2   Isotope Application and Radiopharmaceuticals Division, BARC, Mumbai, Maharashtra, India
› Author Affiliations

Parkinson′s disease (PD) is a progressive neurodegenerative disorder characterized by a selective loss of dopamine in the striatum. Problems remain in the accurate diagnosis of PD. The diagnosis of idiopathic PD is based on the interpretation of clinical signs and symptoms could be incorrect at the time of initial presentation. In vivo imaging of the dopaminergic system has the potential to improve the diagnosis of PD in its early stages. The imaging of dopamine transporter (DAT) with 99m Tc-labeled tropane derivative (TRODAT-1) single photon emission computer tomography/computer tomography (SPECT/CT) has been proposed to be a valuable and feasible means of assessment of the integrity of dopamine neurons. The purpose of this study was to investigate the potential usefulness of 99m Tc-TRODAT-1 imaging in the evaluation of patients with PD and classify into different stages of the disease. SPECT imaging with 99m Tc-TRODAT-1 was conducted in 16 consecutive PD patients (9 men; 7 women) and in 6 age matched healthy volunteers (4 men; 2 women). The images were obtained 3 h after the intra-venous injection of the tracer. Specific uptake in the striatum and its sub-regions, including the putamen and caudate nucleus was calculated and the ratios of specific striatal binding to nonspecific occipital binding were calculated. ANOVA with Dunnett C post-hoc analysis was conducted using SPSS 20. A stepwise reduction in specific striatal uptake of 99m Tc-TRODAT-1 with increasing disease severity between healthy control versus Stage I versus Stage II versus Stage III was found in PD patients (i.e., 3.77 vs. 2.56 vs. 1.57 vs. 0.63, P < 0.05). The changes were magnified by measurement of specific putaminal uptake (1.43 vs. 0.79 vs. 0.54 vs. 0.19, P < 0.05) and specific caudate uptake (1.90 vs. 1.47 vs. 0.73 vs. 0.27, P < 0.05). No remarkable adverse reactions were found in either healthy volunteers or PD patients during or after imaging. 99m Tc-TRODAT-1 is accurate and widely available for the assessment of DAT activity, which might shed light on the integrity of the presynaptic nigrostriatal function. Our preliminary study results confirm the potential of using 99m Tc-TRODAT-1 for DAT measurement, which is clinically important for the staging of PD.



Publication History

Article published online:
23 May 2022

© 2014. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India